Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Toxins (Basel) ; 16(1)2024 01 16.
Article in English | MEDLINE | ID: mdl-38251264

ABSTRACT

Zootoxins are produced by venomous and poisonous species and are an important cause of poisoning in companion animals and livestock in Europe. Little information about the incidence of zootoxin poisoning is available in Europe, with only a few case reports and review papers being published. This review presents the most important zootoxins produced by European venomous and poisonous animal species responsible for poisoning episodes in companion animals and livestock. The main zootoxin-producing animal species, components of the toxins/venoms and their clinical effects are presented. The most common zootoxicoses involve terrestrial zootoxins excreted by the common toad, the fire salamander, the pine processionary caterpillar, and vipers. The lack of a centralized reporting/poison control system in Europe makes the evaluation of the epidemiology of zootoxin-induced poisonings extremely difficult. Even if there are many anecdotal reports in the veterinary community about the exposure of domestic animals to terrestrial and marine zootoxins, the number of published papers regarding these toxicoses is low. Climate change and its consequences regarding species distribution and human-mediated transportation are responsible for the emerging nature of some intoxications in which zootoxins are involved. Although new venomous or poisonous animal species have emerged in regions where they were previously unreported, zootoxins produced by native species remain the main concern in Europe. The diversity of poisonous and venomous animal species and the emerging nature of certain poisonings warrant the continuous update to such knowledge by veterinary professionals and animal owners. This review offers an overview about zootoxin-related poisonings in domestic animals in Europe and also provides important information from a health perspective.


Subject(s)
Animals, Domestic , Climate Change , Animals , Humans , Europe/epidemiology , Livestock
2.
Toxins (Basel) ; 15(7)2023 07 04.
Article in English | MEDLINE | ID: mdl-37505711

ABSTRACT

Exposure to phytotoxins that are present in imported ornamental or native plants is an important cause of animal disease. Factors such as animal behaviors (especially indoor pets), climate change, and an increase in the global market for household and ornamental plants led to the appearance of new, previously unreported plant poisonings in Europe. This has resulted in an increase in the incidence of rarely reported intoxications. This review presents some of the emerging and well-established plant species that are responsible for poisoning episodes in companion animals and livestock in Europe. The main plant species are described, and the mechanism of action of the primary active agents and their clinical effects are presented. Data reflecting the real incidence of emerging poisoning cases from plant toxins are scarce to nonexistent in most European countries due to a lack of a centralized reporting/poison control system. The diversity of plant species and phytotoxins, as well as the emerging nature of certain plant poisonings, warrant a continuous update of knowledge by veterinarians and animal owners. The taxonomy and active agents present in these plants should be communicated to ensure awareness of the risks these toxins pose for domestic animals.


Subject(s)
Animal Diseases , Plant Poisoning , Poisoning , Toxins, Biological , Animals , Plant Poisoning/epidemiology , Plant Poisoning/etiology , Plant Poisoning/veterinary , Animals, Domestic , Europe/epidemiology , Toxins, Biological/toxicity , Poisoning/epidemiology , Poisoning/etiology , Poisoning/veterinary
3.
Equine Vet J ; 55(1): 129-141, 2023 Jan.
Article in English | MEDLINE | ID: mdl-35202500

ABSTRACT

BACKGROUND: Antimicrobial-associated diarrhoea is a common adverse effect of antimicrobial treatment in horses and has been reported following the administration of oral doxycycline. The administration of antimicrobials has also been associated with changes in the equine intestinal microbiota diversity yet has not been explored under doxycycline treatment. OBJECTIVES: To describe the dynamics of the faecal microbial diversity following a 5-day oral administration of doxycycline in healthy horses with Streptococcus zooepidemicus infected tissue chambers. STUDY DESIGN: Experimental prospective cohort study in a single horse group. METHODS: Seven healthy adult horses with S. zooepidemicus infected tissue chambers received oral doxycycline at 10 mg/kg q 12 h for 5-days following the tissue chamber inoculation. Faeces were collected prior to the tissue chamber inoculation and until 28-days post inoculation. Faecal microbiota was characterised by high throughput sequencing of the V4 region of the 16S rRNA gene on the Illumina MiSeq sequencing platform. Bioinformatic analysis was performed with Mothur and statistical analysis were conducted on R Studio. RESULTS: A significant decrease in alpha diversity, characterised by a decrease of richness and diversity, and a decrease in beta diversity, characterised by changes in relative abundance, occurred after initiation of and during the administration of doxycycline. A decrease in Verrucomicrobia and increase in Firmicutes:Bacteroidetes ratio occurred following the initiation of treatment, with a return to initial Firmicutes:Bacteroidetes ratio during the treatment. It took 23 days after discontinuing the treatment for the faecal microbiota to return close to the initial state. MAIN LIMITATIONS: Lack of control population within the study. CONCLUSIONS: Transitory intestinal dysbiosis occurs under oral administration of doxycycline in horses.


Subject(s)
Anti-Infective Agents , Microbiota , Horses/genetics , Animals , RNA, Ribosomal, 16S/genetics , Doxycycline/therapeutic use , Prospective Studies , Feces , Microbiota/genetics
4.
Vaccines (Basel) ; 10(3)2022 Mar 04.
Article in English | MEDLINE | ID: mdl-35335029

ABSTRACT

Vaccination against infectious diseases is a cornerstone of veterinary medicine in the prevention of disease transmission, illness severity, and often death in animals. In North American equine medicine, equine vaccines protecting against tetanus, rabies, Eastern and Western equine encephalomyelitis, and West Nile are core vaccines as these have been classified as having a heightened risk of mortality, infectiousness, and endemic status. Some guidelines differ from the label of vaccines, to improve the protection of patients or to decrease the unnecessary administration to reduce potential side effects. In North America, resources for the equine practitioners are available on the American Association of Equine Practitioners (AAEP) website. Conversely, in small companion animals, peer review materials are regularly published in open access journals to guide the vaccination of dogs and cats. The aims of this review are to present how the vaccine guidelines have been established for small companion animals and horses in North America, to review the equine literature to solidify or contrast the current AAEP guidelines of core vaccines, and to suggest future research directions in the equine vaccine field considering small companion animal strategies and the current available resources in equine literature.

5.
Animals (Basel) ; 11(7)2021 Jul 09.
Article in English | MEDLINE | ID: mdl-34359175

ABSTRACT

Doxycycline (DXC) is a broad-spectrum antibacterial antimicrobial administered to horses for the treatment of bacterial infections which may also affect donkeys. Donkeys have a different metabolism than horses, leading to differences in the pharmacokinetics of drugs compared to horses. This study aimed to describe the population pharmacokinetics of DXC in donkeys. Five doses of DXC hyclate (10 mg/kg) were administered via a nasogastric tube, q12 h, to eight non-fasted, healthy, adult jennies. Serum, urine, synovial fluid and endometrium were collected for 72 h following the first administration. Doxycycline concentration was measured by competitive enzyme immunoassay. Serum concentrations versus time data were fitted simultaneously using the stochastic approximation expectation-maximization algorithm for nonlinear mixed effects. A one-compartment model with linear elimination and first-order absorption after intragastric administration, best described the available pharmacokinetic data. Final parameter estimates indicate that DXC has a high volume of distribution (108 L/kg) as well as high absorption (10.3 h-1) in donkeys. However, results suggest that oral DXC at 10 mg/kg q12 h in donkeys would not result in a therapeutic concentration in serum, urine, synovial fluid or endometrium by comparison to the minimum inhibitory concentration of common equine pathogens. Further studies are recommended to identify appropriate dosage and dosing intervals of oral DXC in donkeys.

6.
J Vet Pharmacol Ther ; 44(5): 766-775, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34057219

ABSTRACT

The objectives of this study were to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and the efficacy of oral administration of doxycycline (DXC) in horses with Streptococcus zooepidemicus tissue infections. Tissue chambers (TC) were implanted subcutaneously in the cervical region of 7 horses and inoculated with a single S. zooepidemicus isolate with a minimum inhibitory concentration (MIC) of 0.25 µg/ml, determined by agar dilution. Doxycycline hyclate (10 mg/kg, orally, q 12 h, for 5 days) mixed with poloxamer gel was started following inoculation. The TC fluid was sampled prior to and following inoculation for cytology analysis, quantitative culture, and DXC determination. Plasma DXC concentrations were measured over 48 h following the last dose of DXC administered. The mean plasma peak concentration (Cmax ) of DXC was 0.32 µg/ml, and concentrations above the MIC were only reached in 3 TC samples. In plasma, mean T > MIC was 2.4 h, mean Cmax /MIC was 1.30, and mean AUClast /MIC was 11.63 h. These PK/PD indices did not reach the suggested targets for DXC treatments of infections, and the TC abscessed in all horses. This is the first study to evaluate the recommended dose of DXC in horse in an infection model.


Subject(s)
Doxycycline , Streptococcus equi , Administration, Oral , Animals , Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Horses , Microbial Sensitivity Tests/veterinary
7.
Can Vet J ; 61(7): 724-730, 2020 07.
Article in English | MEDLINE | ID: mdl-32655155

ABSTRACT

In the summer of 2017, 4 horses were diagnosed with septic fibrinous pericarditis at the Western College of Veterinary Medicine, Saskatoon. This case series occurred after a significant outbreak of forest tent caterpillars (Malacosoma disstria) in the province during that spring. Three horses were immediately euthanized, and treatment was attempted in 1 mare. This is the first case series of pericarditis possibly associated with the ingestion of forest tent caterpillars to be reported in western Canada. Although cause-effect is not proven, it is prudent to prevent the ingestion of caterpillars by horses. Key clinical message: Septic fibrinous pericarditis, a rare condition in horses, has previously been linked to outbreaks of eastern tent caterpillars. A similar link might exist in this case series.


Péricardites fibrineuses septiques chez quatre chevaux saskatchewanais consécutive à une infestation de chenilles de livrée des forêts en 2017. Au cours de l'été 2017, quatre chevaux ont été diagnostiqués avec une péricardite fibrineuse septique au Western College of Veterinary Medicine de Saskatoon. Ces cas ont été présentés après une sévère infestation printanière de chenilles de livrée de forêts (Malacosoma disstria) dans la province de la Saskatchewan, reportée au printemps. Trois chevaux ont été immédiatement euthanasiés et une jument a été hospitalisée pour traitement. Ceci est le premier rapport décrivant la possible association entre des cas de péricardite chez des chevaux et l'ingestion de chenilles de livrée de forêts dans l'Ouest canadien. Même si le lien de cause à effet n'est pas prouvé, il est prudent d'éviter l'ingestion de ces chenilles processionnaires par les chevaux.Message clinique clé :La péricardite fibrineuse septique, une condition rare chez les chevaux, a précédemment été liée à des flambées de livrées des forêts. Un lien similaire pourrait exister dans la présente série de cas.(Traduit par les auteurs).


Subject(s)
Horse Diseases , Pericarditis , Animals , Disease Outbreaks/veterinary , Euthanasia, Animal , Female , Forests , Horse Diseases/epidemiology , Horses , Larva , Pericarditis/epidemiology , Pericarditis/veterinary , Saskatchewan/epidemiology
8.
Can Vet J ; 58(5): 466-471, 2017 May.
Article in English | MEDLINE | ID: mdl-28487590

ABSTRACT

Castration with primary wound closure reportedly has lower complication rates and shorter recovery periods compared to castration with second intention healing. However, little is known about risk factors associated with complications using primary wound closure. Medical records of 159 horses castrated and having primary wound closure were reviewed. Main short-term complications were: scrotal hematoma in 12 horses (7.6%), signs of colic in 6 horses (3.8%), fever in 4 horses (2.5%), and peri-incisional edema in 3 horses (1.9%). As for long-term complications, 24 out of 105 (23%) horses sustained some form of edema. One horse was euthanized because of a suspected inguinal abscess. Among tested parameters, horses aged 3 to 6 years old and French trotters appeared to be more at risk of developing complications. Intraoperative ligation of the cremaster muscle and use of electrocautery prevented complications. Overall, client satisfaction was excellent (98%).


Complications et facteurs de risque de la castration avec fermeture des plaies par première intention : étude rétrospective chez 159 chevaux. La castration avec fermeture des plaies par première intention a un taux de complications plus faible et une période de convalescence plus courte que la castration avec cicatrisation par seconde intention. Cependant, on en sait peu sur les facteurs de risque associés aux complications en utilisant la technique de fermeture des plaies par première intention. Les dossiers médicaux de 159 chevaux castrés de cette façon ont été examinés. Les complications à court terme sont les suivantes: hématome scrotal chez 12 chevaux (7,6 %), signes de coliques chez 6 chevaux (3,8 %), fièvre chez 4 chevaux (2,5 %) et de l'œdème péri-incisionel chez 3 chevaux (1,9 %). En ce qui concerne les complications à long terme, 24 sur 105 (23 %) chevaux ont présenté un certain degré d'œdème. Un cheval a été euthanasié à cause d'un probable abcès inguinal. Parmi les paramètres testés, les chevaux âgés de 3 à 6 ans et les Trotteurs Français semblent être plus à risque de développer des complications. En outre, la ligature peropératoire du muscle crémaster et l'utilisation du bistouri électrique semblent prévenir les complications. Dans l'ensemble, la satisfaction des clients était excellente (98 %).(Traduit par les auteurs).


Subject(s)
Castration/veterinary , Horses/surgery , Postoperative Complications/veterinary , Wound Healing , Animals , Castration/adverse effects , Horse Diseases/epidemiology , Horse Diseases/prevention & control , Male , Postoperative Complications/epidemiology , Postoperative Complications/prevention & control , Retrospective Studies , Risk Factors , Wounds and Injuries/veterinary
9.
J Appl Physiol (1985) ; 89(1): 273-82, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10904062

ABSTRACT

MTII, an agonist of melanocortinergic receptors, is a well-documented anorexigenic agent in rats. Many investigators have reported its effects on feeding without considering concurrent alterations in other behaviors. Accordingly, we performed studies to simultaneously measure nocturnal feeding, drinking, activity, and temperature of rats after intracerebroventricular (third ventricle) administration of a wide dose range of MTII (0.05-500 ng). We observed that MTII modulates these physiological parameters in a dose-dependent manner. Low doses of MTII (0.05 ng) caused reductions in feeding without alterations in body temperature, drinking, or activity. In contrast, hyperthermia and disrupted drinking patterns, along with food intake reductions, were evident at doses exceeding 50 ng. The fact that low doses altered only feeding, whereas higher doses affected a range of parameters, suggests that certain melanocortin-induced behavioral changes may be mediated by distinct populations of melanocortin receptors with varying affinities or that those changes seen at higher doses may be nonspecific in nature.


Subject(s)
Body Temperature/drug effects , Drinking Behavior/drug effects , Feeding Behavior/drug effects , Motor Activity/drug effects , alpha-MSH/analogs & derivatives , Animals , Behavior, Animal/drug effects , Injections, Intraventricular , Kinetics , Male , Monitoring, Physiologic , Obesity/physiopathology , Rats , Rats, Sprague-Dawley , Third Ventricle , alpha-MSH/pharmacology
10.
J Histochem Cytochem ; 48(3): 407-14, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10681394

ABSTRACT

Acidic fibroblast growth factor (aFGF) is a heparin binding protein that displays pleiotropic activity. The purpose of this study was to document the presence of the translated aFGF product, its mRNA, and its location in the colon. mRNA was extracted from bovine large intestine and reverse transcribed to cDNA. Nested-primer PCR was used to determine the presence of mRNA using primers homologous to the previously published bovine aFGF cDNA. Purification of translated aFGF was performed using an established HPLC protocol. Western blot analysis of the HPLC fractions was performed using two epitope-independent antibodies against aFGF. Immunohistochemistry employed these antibodies to determine the locus of aFGF expression. The nested-primer PCR product of predicted size was homologous to the published bovine aFGF mRNA sequence, as determined by DNA sequencing. Intestinal aFGF had a mass similar to bovine aFGF isolated from other tissues, and immunocrossreacted with two peptide-based, epitope-independent anti-aFGF antisera on Western blotting. Immunohistochemical analysis of large intestine using these two independent antisera localized aFGF within the myenteric plexus. These data demonstrate that aFGF is present within the myenteric plexus of the enteric nervous system.


Subject(s)
Enteric Nervous System/metabolism , Fibroblast Growth Factor 1/metabolism , Intestine, Large/metabolism , Animals , Blotting, Western , Cattle , Electrophoresis, Polyacrylamide Gel , Humans , Immunohistochemistry , Intestine, Large/anatomy & histology , Intestine, Large/innervation , Myenteric Plexus/metabolism , Polymerase Chain Reaction , RNA, Messenger/metabolism
11.
Neuropeptides ; 32(6): 491-7, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9920446

ABSTRACT

Melanocortinergic neurons are believed to play a role in the control of food intake. Melanocortin receptor agonists and antagonists modulate feeding in several mouse models of chemically and genetically induced hyperphagia. To date, little information is available describing the role of this neurological system in the control of the natural feeding cycle in genetically intact rats. To evaluate the involvement of melanocortins in spontaneous nocturnal feeding, the synthetic melanocortin receptor agonist, MTII and the antagonist, SHU9119 were administered ICV (third ventricle) alone and in combination. Dose-dependent inhibition or stimulation of food intake was observed with MTII or SHU9119, respectively. Co-injections containing equal concentrations of MTII and SHU9119 resulted in food intake that was indistinguishable from controls. Food intake patterns observed in studies in which various dose combinations of MTII and SHU9119 were co-injected are consistent with the concept that both affect feeding by acting on similar melanocortin receptors. The hypothesis that effects of melanocortins on feeding may be mediated via an NPY related pathway was tested by co-injecting MTII and NPY in a 2-h satiated food intake paradigm. MTII inhibited food intake induced by 5.0 microg hNPY in a dose dependent manner with the highest dose tested abolishing the NPY feeding response. The studies suggest that melanocortins act via specific receptors to control food intake in rats, possibly via an NPY related pathway. If similar neurochemical processes operate in humans, selectively modulating specific melanocortin receptor signaling may be an approach to the treatment of human obesity.


Subject(s)
Feeding Behavior/drug effects , Melanocyte-Stimulating Hormones/pharmacology , Animals , Appetite Stimulants/pharmacology , Drug Interactions , Injections, Intraventricular , Male , Melanocyte-Stimulating Hormones/agonists , Melanocyte-Stimulating Hormones/antagonists & inhibitors , Neuropeptide Y/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Corticotropin/agonists , Receptors, Corticotropin/antagonists & inhibitors , Satiety Response/drug effects , Satiety Response/physiology , alpha-MSH/analogs & derivatives , alpha-MSH/pharmacology
12.
J Invest Dermatol ; 104(5): 850-5, 1995 May.
Article in English | MEDLINE | ID: mdl-7537778

ABSTRACT

Acidic fibroblast growth factor (aFGF) is a potent mitogenic and chemotactic agent for vascular endothelial cells, dermal fibroblasts, and epidermal keratinocytes, the principal cellular constituents of skin. To explore its potential to heal chronic dermal wounds, we applied pure recombinant human aFGF topically to full-thickness excisional injuries in healing-impaired genetically diabetic mice. Transformation of the nonlinear percent initial wound areas as a function of time to linear rates of tissue ingrowth from the original wound edges showed that aFGF increased wound closure in a dose-dependent manner. Optimal 3-micrograms/cm2 doses of aFGF nearly tripled the linear rate of healing. The median time to complete closure decreased from 46 d in vehicle-treated wounds to only 16 d in those treated with aFGF. Histomorphometric analyses established that aFGF increased granulation tissue formation and reepithelialization throughout healing. Vehicle- and aFGF-treated wounds appeared to be histologically equivalent by the time of closure. Therefore, aFGF has potential therapeutic applications for promoting healing of dermal ulcers, especially in healing-impaired individuals.


Subject(s)
Diabetes Mellitus, Experimental/physiopathology , Fibroblast Growth Factor 1/pharmacology , Wound Healing/drug effects , Animals , DNA/biosynthesis , Dose-Response Relationship, Drug , Humans , Mice , Mice, Inbred C57BL , Organ Culture Techniques , Recombinant Proteins/pharmacology , Skin/metabolism , Stimulation, Chemical , Wounds and Injuries/drug therapy , Wounds and Injuries/pathology
13.
Growth Factors ; 7(1): 1-14, 1992.
Article in English | MEDLINE | ID: mdl-1380253

ABSTRACT

Acidic fibroblast growth factor (aFGF) is a potent mitogen in vitro for many cells of ectodermal and mesodermal embryonic origin including skin-derived epidermal keratinocytes, dermal fibroblasts and vascular endothelial cells. Based on the mitogenic activity for these skin-derived cells, we tested the ability of topically applied aFGF to promote healing of full-thickness dermal wounds in healthy rodents. Low doses of aFGF can produce almost a two-fold maximum acceleration in the rate of closure of full-thickness dermal punch biopsy wounds in young healthy mice and rats. The mitogen also produces a 3 to 4 day acceleration in the time to complete closure in rats. Quantitative histomorphometric analysis of wound tissue shows that aFGF induces a marked stimulation of angiogenesis, granulation tissue formation and the growth of new epithelium, but does not promote dermal contraction. Application of aFGF to linear incisions in rat skin produces a transient increase in wound tensile strength accompanied by enhanced cellularity and deposition of collagen. Therefore, aFGF functions as a pharmacological agent that can accelerate dermal wound healing in rodents and could act therapeutically to promote dermal tissue repair in humans.


Subject(s)
Fibroblast Growth Factor 1/pharmacology , Skin/injuries , Wound Healing/drug effects , 3T3 Cells , Animals , Cattle , Dose-Response Relationship, Drug , Fibroblast Growth Factor 1/genetics , Genes, Synthetic , Humans , Male , Mice , Mice, Inbred ICR , Organ Culture Techniques , Rats , Rats, Inbred Strains , Recombinant Proteins/pharmacology , Skin/drug effects , Skin/pathology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...